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Background: The amyloid precursor protein (APP) is a key molecule in Alzheimer disease. Its localization at the cell
surface can trigger downstream signaling and APP cleavages. APP trafficking to the cell surface in neurons is not
clearly understood and may be related to the interactions with its partners. In this respect, by having homologies
with kinesin light chain domains and because of its capacity to bind APP, PAT1 represents a good candidate.
Results: We observed that PAT1 binds poorly APP at the cell surface of primary cortical neurons contrary to
cytoplasmic APP. Using down and up-regulation of PAT1, we observed respectively an increase and decrease of
APP at the cell surface. The increase of APP at the cell surface induced by low levels of PAT1 did not trigger cell
death signaling.
Conclusions: These data suggest that PAT1 slows down APP trafficking to the cell surface in primary cortical
neurons. Our results contribute to the elucidation of mechanisms involved in APP trafficking in Alzheimer disease.
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Amyloid Precursor Protein (APP) is a key molecule in
Alzheimer disease (AD) by the generation of its metabo-
lites [1,2]. APP at the cell surface is required for its
cleavages. Beside its cleavages, APP can receive signals
transduced through Go to induce neuronal migration
and outgrowth, synapse differentiation at the neuro-
muscular junction in Drosophila or cell death [3-10].
The generation of APP cleavages following this signaling
has not been reported. Some molecules like reelin, able
to induce neurite outgrowth in primary neurons, pro-
mote a rapid traffic of APP to the cell surface [11]. Inter-
estingly, this increase of APP at the cell surface is
required for reelin-induced neurite outgrowth suggesting
that APP at the cell surface triggers some signaling in
this model [11]. Consequently, APP trafficking to the
cell surface appears crucial, but its mechanisms remain
poorly investigated. APP is a fast axonal transported
protein along the microtubules, involving kinesin and
Rab3 GTPase activity [12-21]. The role of APP binding* Correspondence: bernadette.allinquant@inserm.fr
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article, unless otherwise stated.with its partners either in the N or in the C-terminal
domains has been poorly investigated and some of these
interactions could be involved in APP trafficking. The
neuronal sorting protein-related receptor SorLA/LR11, a
retromer-associated protein, interacts with the APP
carbohydrate-linked domain and retains APP in Golgi
[22,23]. Sortilin, a VPS10p-domain receptor, related to
SorLA interacts with both the extracellular and intra-
cellular domains of APP in neurites and regulates APP
trafficking to lysosomes and lipid rafts [24]. Mint pro-
teins bind APP and ADP-ribosylation factors suggesting
that Mint proteins can regulate vesicular trafficking of
APP and its endocytosis [25]. Recently, Mint3 adaptor
has been shown necessary for export of APP from the
Golgi to a LAMP1+ compartment [26]. AP-4 has been
shown to be important for the APP export from the
Golgi in HeLa cells [27]. Most of APP partners are local-
ized in the distal part of the C-terminal domain, prob-
ably due to its structure having two type I reverse turns,
the first one at the TPPEE sequence [28,29]. Conse-
quently, the APP cytoplasmic juxtamembrane domain
may be less accessible to partners unless it is unmasked
after caspase cleavage. The PAT1 (Protein interacting with
APP tail 1) also called APPBP2 (Amyloid protein-bindingCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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juxtamembrane domain and bearing repeat homologies to
kinesin light chains has been reported to increase APP
trafficking to the cell surface when co-transfected with
APP in COS cells [30]. PAT1 is expressed in many human
tissues at variable levels and in many cell lines [31]. More
recently, a polymorphism of the PAT1/APPBP2 gene was
shown at the origin of sequence differences in PAT1,
Ara67 and APPBP2 [32]. PAT1a is 99% identical to PAT1
and completely identical to APPBP2. Ara67 is 99.6%
identical to PAT1 [31,32]. PAT1a when overexpressed in
neuroblastoma cells with APP, induces an increase of APP
at the cell surface [32]. We have previously shown that
overexpression of the APP-PAT1 binding domain in the
cytoplasm of primary neurons through the help of an
internalization vector, leads to a very rapid increase of
APP at the cell surface bound to a low amount of PAT1
triggering a cell death signal [33]. In this model, PAT1 was
trapped by the APP-PAT1 binding domain disrupting
PAT1 from its interactions with endogenous APP, suggest-
ing that the binding of PAT1 with endogenous APP pre-
vents its trafficking to the cell surface. In order to address
the role of PAT1 in APP trafficking at the cell surface in
primary neurons, we down and up-regulated PAT1 and
observed that APP at the cell surface is dependent on a
low amount of PAT1 suggesting that the binding of PAT1
to APP keeps APP in the cytoplasm.
Results
Colocalization of APP and PAT1 is poorly present at the
cell surface of neurons
We first observed in primary cortical neurons that
paraformaldehyde (PFA) fixation at 4% caused little
permeabilization at the cell surface allowing some PAT1
detection under the cell surface while additional per-
meabilization by 0.2% Triton X 100 allowed to detect
more PAT1 in the cytoplasm (Figure 1A). The Giantin a
Golgi marker is detected after additional permeabilization
with 0.2% Triton X 100 only.
PAT1 was detected close to the cell surface of soma
and neurites. Double immunostaining for APP and
PAT1, performed after 4% PFA fixation only, reveal little
co-localization close to the cell surface contrary to what
observed in the cytoplasm when the fixed cells were
then permeabilized with 0.2% Triton X 100. Pearson’s
coefficient shows a significant difference (p < 0.001) be-
tween the colocalization of APP and PAT1 detected after
fixation in PFA only and the colocalization observed when
the fixation is followed by an additional permeabilization
in Triton X 100 (Figure 1B).
Immunoprecipitation of APP from total neuronal
extracts show co-immunoprecipitation of PAT1 as
expected. In that case the ratio of APP to PAT1 (Mean ±
SEM: 2.7 ± 0.2) was close to that observed in lysates beforeimmunoprecipitation (Mean ± SEM: 2.6 ± 0.1). After cell
surface biotinylation this ratio was significantly higher
(Mean ± SEM: 6.0 ± 0.2) (Total Co-IP vs Cell surface Co-
IP: p < 0.001) (Figure 1C). These data confirm that at cell
surface the amount of PAT1 attached to APP is lower than
in the cytoplasm.
Down and up-regulation of PAT1 respectively increases
and decreases APP at the cell surface of neurons
In order to investigate if PAT1 levels can modulate the
trafficking of APP to the cell surface we down and
up-regulated PAT1. Down-regulation of PAT1 was per-
formed by the help of specific siRNAs. The decrease of
PAT1 level in primary neurons was checked 66 h after
PAT1 siRNAs addition both by immunocytochemical
staining for PAT1 without Triton X 100 and immuno-
blots from cell extracts (Figure 2A-B). A significant de-
crease of PAT1 level was observed in primary neurons
treated with PAT1 siRNAs for 66 h comparatively to
control (ctrl) cells in absence of treatment (ctrl vs PAT1
siRNAs: p < 0.001) while no difference of PAT1 levels
was observed using GAPDH siRNAs, as control siRNAs
(ctrl vs GAPDH siRNAs: NS) (Figure 2A-B). The down-
regulation of PAT1 or GAPDH did not modify the level
of total APP in neuronal extracts (Figure 2B).
The localization of APP in cortical neurons was checked
in primary neuronal culture treated with PAT1 siRNAs
for 66 h. Confocal analyses of immunocytochemical
APP detection in absence of Triton X 100 showed a sig-
nificant increase of APP at the cell surface in presence
of low levels of PAT1 (ctrl vs PAT1 siRNAs: p < 0.001).
This increase of APP was present both in soma and
neurites (Figure 2C, upper panel). Cell surface biotinyl-
ation performed after 66 h of PAT1 siRNAs treatment
confirmed this APP increase at the cell surface (ctrl vs
PAT1 siRNAs: p < 0.001) (Figure 2D, upper panel). As
total APP was not modified in PAT1 siRNAs conditions
(Figure 2B), these data suggest that the APP increase at
the cell surface is induced by low levels of PAT1 and
not by changes in total APP levels. No difference of
APP at the cell surface was observed when the neurons
were treated with GAPDH siRNAs (ctrl vs GAPDH
siRNAs: NS) (Figure 2C-D, lower panels). We did not
observe cell death in neurons treated with PAT1
siRNAs, nor with GAPDH siRNAs, suggesting that the
increase of APP at the cell surface, in conditions of
PAT1 low levels did not induce cell death (Figure 3).
Conversely, up-regulation of PAT1 was performed by
transfection of PAT1-myc in primary cortical neurons.
Then, the cells were fixed 24 h later, and processed for
myc and APP double immunolabeling. Cells overexpress-
ing PAT1-myc have little APP at the cell surface as ob-
served by immunolabeling performed after PFA fixation
in absence of any further permeabilization (Figure 4A).
Figure 1 APP and PAT1 colocalize poorly at the cell surface of primary neurons. A) Neurons at 5 DIV were fixed in PFA 4% for 30 min (left
panel). After fixation, an additional permeabilization in 0.2% Triton X 100 was performed (right panel). In both cases cells were immunolabeled for
Giantin or PAT1. Immunocytochemistry was analyzed by confocal microscopy. One representative immunocytochemical staining out of 4 independent
experiments is presented. Scale bar: 10 μm. B) APP and PAT1 double immunolabeling was performed in neurons at 5 DIV fixed with PFA 4%
only (left panel) and followed by 0.2% Triton X 100 (right panel). Anti-APP Cter polyclonal and monoclonal PAT1 antibodies were used as primary
antibodies. Pearson’s coefficient was evaluated following confocal microscopy analyses and quantifications in Volocity software. Data presented
are the mean ± SEM of 4 independent experiments. C) Ratio of APP to PAT1 before (Input) and after immunoprecipitation of APP in total extracts (Total
Co-IP) and after cell surface biotinylation (Cell surface Co-IP). Immunoprecipitation of APP was performed with the anti-APP Cter polyclonal antibody.
10.106 cells at 6 DIV were used for each condition. 40 μg of cell extracts before immunoprecipitation were loaded (Input). Control immunoprecipitation
in absence of primary antibody is presented (Ctrl). Detection of APP in western blotting was performed using the anti-APP-Nter A4 antibody.
Data presented are the mean ± SEM of 3 independent experiments. Representative immunoblot and histogram of the ratio of APP to PAT1 in
arbitrary units (AU) are presented.
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tions of additional permeabilization with Triton X 100,
more endogenous APP within the cytoplasm colocalized
with PAT1-myc in transfected cells (Figure 4B), asindicated by Pearson’s coefficient. A significant in-
crease of Pearson’s coefficient (p < 0.001) was observed
in conditions of additional permeabilization compara-
tively to conditions of PFA fixation only (Figure 4A-B).
Figure 2 Down-regulation of PAT1 increases APP at the cell surface of primary neurons. Neurons at 2 DIV were treated with either PAT1
siRNAs or GAPDH siRNAs comparatively to control cells (Ctrl) in absence of treatment. A-B: After 66 h the cells were fixed and processed for PAT1
immunocytodetection (A) or extracted for western blots (B). (A) Immunocytochemistry was analyzed by confocal microscopy and quantified by
Image J. Data are expressed in integrated density/cell in arbitrary units (AU). Two representative immunolabelings of PAT1 of each condition are
presented. (B) 40 μg of cell extracts were loaded for western blotting. The level of PAT1 or of APP reported to actin was expressed in arbitrary
units (AU). Data in A and B are the mean ± SEM of 4 independent experiments and of 3 experiments for right panel in B. C-D: After 66 h of
PAT1 siRNAs or GAPDH siRNAs, the cells were fixed by and processed for APP immunodetection (C) or for cell surface biotinylation (D). (C) APP
immunocytochemistry was analyzed by confocal microscopy and quantified with Image J. Data are expressed in integrated density/cell in
arbitray units (AU). Three representative images of each condition are presented. (D) Cell surface biotinylation was performed on 106 cells. NCAM was
used as internal control of membrane loading for cell surface biotinylation. The level of APP in biotinylated membranes was reported to NCAM and
expressed in arbitrary units (AU). Data are the mean ± SEM of 3 independent experiments. In the whole figure immunocytochemistry was performed
using the anti-APP-Nter A4 antibody. The anti-APP Cter polyclonal antibody was used for western blotting in 2B (right panel) and the anti-APP-Nter A4
antibody was used in 2D. Scale bar: 10 μm.
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significant lower ratio of APP/NCAM than in the control
conditions, confirming immunocytochemical data (Ctrl vs
PAT1-myc: p = 0.006) (Figure 4C). The total APP leveldetected in transfected cells by immunolabeling in condi-
tions of additional permeabilization with Triton X 100,
was not significantly different to that of non-transfected
cells suggesting that the overexpression of PAT1-myc does
Figure 3 Cell viability of neurons after treatment by PAT1 siRNAs
or GAPDH siRNAs. Cells in absence of treatment (Ctrl), and after 66 h
of PAT1 siRNAs or GAPDH siRNAs were tested for cell viability using the
Cell Titer-Glo-Luminescent Cell Viability kit. Data are expressed in % of
control. Data are the mean ± SEM of 2 independent experiments.
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quently, the decrease of APP at the cell surface is induced
by the overexpression of PAT1-myc and not by changes in
APP total levels under these conditions.
The whole data suggest that PAT1 slows down APP
trafficking to the cell surface.
Discussion
Using down and up-regulation of PAT1 in primary
neurons, we show here that PAT1 is involved in APP
trafficking to the cell surface.
PAT1 down-regulation through siRNAs causes an in-
crease of APP at the cell surface while up-regulation of
PAT1 shows very little if any APP close to the plasma
membrane. PAT1 down-regulation experiments fit with
what we observed when PAT1 was mislocalized by over-
expressing the APP-PAT1 binding domain [33]. In that
case, PAT1 was attached to the APP-PAT1 binding do-
main in the cytoplasm detrimental to endogenous APP.
The binding of endogenous PAT1 to the APP-PAT1 do-
main internalized through a cell permeable peptide led
to a rapid increase of APP at the cell surface, as early as
one hour. In this case APP migrating at cell surface had
a very low level of PAT1, while the internalized APP-
PAT1 binding domain was also able to interact in a tri-
partite interaction with APP and PAT1 in the cytoplasm.
Indeed, we showed that this increase of APP and of its
homolog Amyloid Precursor like Protein 2 (APLP2) at
the cell surface induced a cell death signal with down-
stream events like translocation of SET from the nucleus
to the cytoplasm. In this model the level of PAT1 still at-
tached to APP at the cell surface was lower than incontrol conditions, and probably lower than in PAT1
siRNAs conditions as well. In addition, we cannot
exclude that other partners able to interact with PAT1
were probably mislocalized with PAT1 and could act in
the cell death signal induced by the increase of APP at
the cell surface. In the present study, in conditions
where PAT1 was down-regulated by siRNAs, APP
reached rapidly the cell surface, as if it was liberated
from some anchor in the cytoplasm but did not induced
cell death, probably because about 50% of PAT1 was still
present and not mislocalized. Down-regulation using
siRNAs remains more stable contrary to the very transi-
ent efficiency of antisense oligonucleotides strategy
which is useful for a rapid signal induced at the time of
its highest efficiency, as we observed with the APP-
PAT1 binding domain peptide but which can mask some
events [33]. We don’t know precisely at what level of
PAT1 within the neuron, APP starts to migrate to the
cell surface. In control conditions, we observed here that
the amount of PAT1 interacting with APP at the cell
surface is lower than with the total level of APP interact-
ing mainly within the cytoplasm, meaning that at the cell
surface PAT1 is poorly required.
The down-regulation data obtained with PAT1 siRNAs
fit with the PAT1 up-regulation results, where little APP
reached the cell surface while it is present deeply in the
cytoplasm co-localizing with PAT1 probably by direct
interaction. Our data fit with what observed with Ara67/
PAT1 which binds to androgen receptor in the cyto-
plasm of cell lines overexpressing these two partners
suppressing the migration of androgen receptor to the
nucleus and its transactivation [31].
Whether the ligands acting on a specific receptor and
inducing an increase of APP at the cell surface are
related to a disruption of the interaction with PAT1
remain to be elucidated. In the reelin signaling pathway
the increase of APP at the cell surface was also observed
in presence of high levels of Disabled-1, the reelin
signaling molecule, able to bind the APP cytoplasmic
distal domain [34]. As PAT1 binds the APP cytoplasmic
juxtamembrane domain, in pathological conditions where
there is an increase of the neuronal APP cleaved in
its cytoplasmic domain by a caspase [35-38], one can
wonder if the uncleaved APP migrates rapidly to the
cell surface to trigger a cell death signal stimulating the
deleterious effect.
Previous report has shown that the anterograde trans-
port of APP was independent of its C-terminal domain
but required the Rab3GTPase activity for recruitment of
kinesin 1C to vesicles containing APP allowing to interact
with microtubules [21]. Nothing is known if Rab3GTPase
activity is necessary for the retrograde APP trafficking
as well as its trafficking to the cell surface. One cannot
exclude that PAT1 having several repeats of kinesin
Figure 4 Up-regulation of PAT1 in primary neurons results in a strong colocalization with APP in the cytoplasm but not at the cell
surface. A-B. PAT1-myc was overexpressed by transfection in primary neurons at 5 DIV. 24 h later cells were fixed by PFA 4% only (A) or followed
by 0.2% Triton X 100 (B). Immunolabeling for PAT1-myc (Alexa-488) and endogenous APP (Cy3) was performed and analyzed by confocal microscopy.
Two representative images in each condition are presented. In (A) immunolabeling was performed using the anti-myc tag polyclonal #06-549 and the
anti-APP-Nter A4 antibody. In (B) the anti-myc tag MABE282 and the anti-APP-Cter polyclonal antibodies were used for immunolabeling. Quantification
of colocalization using Volocity software was expressed by Pearson’s coefficient (upper panel). Data presented are the mean ± SEM of 3 independent
experiments. Quantification of total APP in conditions of 0.2% Triton X 100 was performed in 23 transfected and 42 non-transfected cells (Ctrl)
out of 3 independent experiments. Data are expressed in integrated density / cell in arbitrary units (AU) and represents the mean ± SEM (lower
panel). Scale bar: 10 μm. C) Cell surface biotinylation was performed on PAT1-myc overexpressed cells comparatively to control cells (Ctrl). Ex-
periments were performed on 10.106 cells 24 h after transfection. NCAM was used as internal control of membrane loading for cell surface bio-
tinylation. The level of APP in biotinylated membranes was reported to NCAM and expressed in arbitrary units (AU). Data are the mean ± SEM of
3 independent experiments. Western blotting were performed using the anti-APP-Nter A4 and the anti-NCAM antibodies.
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containing vesicles to move by competing with kinesin
1C in the interaction with microtubules [21]. Our
results contradict the data obtained in APP and PAT1
or PAT1a double transfected COS and neuroblastomacells [30,32]. PAT1 binding domain to APP has not been
determined and as PAT1/PAT1a contains several re-
peats, it is possible that PAT1/PAT1a acts in a multipar-
tite APP interaction. In case of double transfected cells
it would have been interesting to evaluate the ratio of
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cytoplasm. The modulation of the level of endogenous
PAT1 in primary differentiated neurons could represent
more physiological conditions.
In addition to cell signaling, increases of APP at the
cell surface may induce APP cleavages. However, we
could not establish an increase of APP cleavages either
in alpha or beta secretase in PAT1 down-regulation con-
ditions (not shown). This may be explained by low
detectable amyloid products in our primary neurons.
Since PAT1 poorly binds APP at the cell surface, it is
possible that PAT1 may have other partners and func-
tion. The role of PAT1 in pathology has not been eluci-
dated. It is highly expressed in breast cancers with poor
diagnosis [39], in ovarian adenocarcinoma tumors [40],
but also in neuroblastomas [41], and desmoplastic me-
dulloblastoma cerebellar tumors [42]. PAT1 binds also
to the C-terminal domain of the herpes simplex virus
type 1 Us11 gene product and probably this interaction
plays a role in the intracellular movement of viral com-
ponents [43]. Changes in PAT1 expression in Alzheimer
disease have not been yet investigated but could have
consequences in APP signaling and cleavages.
Conclusion
In primary cortical neurons APP is poorly associated to
its partner PAT1 at the cell surface contrary to what
observed in the cytoplasm. We used down and up-
regulation of PAT1 in primary neurons and observed
that APP respectively increases and decreases at the cell
surface. The modulation of APP at the cell surface
through PAT1 levels can represent a way to control the
cell surface signaling events and APP cleavages. These
data contribute to the understanding of mechanisms
involved in Alzheimer disease.
Methods
Ethics statement
The protocols of animal anesthesia were performed
according to the recommendations of the French National
Committee (87/848) and European Economic Community
(86/609/EEC) and were approved by the local ethics com-
mittee (Direction départementale des services vétérinaires
de Paris, service de la protection et santé animales et de la
protection de l’environnement).
Primary cortical neurons
Primary cortical neurons were prepared from E16 mouse
embryos from Swiss strain mice as previously described
[33]. Briefly, dissociated cells were plated on polyornithine-
coated glass coverslips for immunochemistry and on
plastic dishes for cell surface biotinylation, immunopre-
cipitation and cell death quantification. Cells were
plated at 15 × 104 cells/cm2 for control and siRNAsexperiments and at 30 × 104 cells/cm2 for transfection
experiments. Cell death experiments were performed
on ELISA coated dishes at 20 × 103 cells/well.
Down-regulation of PAT1
Small interfering RNA duplexes (siRNAs) were used
for down-regulation of PAT1 siRNAs (J-059477-10 and
J-059477-12, Thermo Fischer Scientific, St Leon-Rot,
Germany) at the final concentration of 100 nM. GAPDH
siRNAs were used as siRNA negative control (AM4624,
Thermo Fisher Scientific). Briefly, siRNAs were internal-
ized into primary neurons with the help of penetratin
(MP Biomedicals, Illkirsch, France) in a ratio of 1 to 10
(siRNAs to penetratin) as previously described [33].
siRNAs were mixed to penetratin at room temperature
for 30 min, before their addition in the medium. Cells
were incubated for 4 h at 37°C. Then half fresh medium
was added and left at 37°C for 66 h.
Human PAT1 cloning
Human total brain RNA (Ozyme, Saint-Quentin-en-
Yvelines, France) was converted into cDNA by high
capacity cDNA reverse transcription kit (Life Technolo-
gies, Saint Aubin, France) following the manufacturer’s
instructions. Human PAT1 full length coding sequence
was generated by forward primer (Eurofins MGW Operon,
Les Ullis, France): 5′-ATGGCGGCCGTGGAACTAGA-3′
and reverse primer: 5′-AATGTCGAGGGACCGAGC
TGC-3′. The amplified fragment was used as a template
to amplify the same region with restriction sites for
EcoRI and NotI respectively, by the forward primer:
5′-TATCGAGAATTCATGGCGGCCGTGGA-3′ and re-
verse primer: 5′-ACCGAGCTGCGGCCGCTTAAT-3′ in
order to be cloned into pcDNA3.1/myc-His vector (Life
Technologies).
Plasmids were transformed into E.Coli strain XL10-
Gold ultracompetent cells (Agilent Technologies, Les
Ullis, France). Positive colonies were selected by PCR
and the generated plasmid was sequenced.
Antibodies
The supernatant of the hybridoma cell line mAb26 [30]
was used as the antiserum against PAT1. It was used
diluted to 1/20 for immunocytochemistry and to 1/200
for western blotting.
The other antibodies were purchased and diluted as
follows:
Rabbit polyclonal anti-Giantin (Abcam Cat# ab24586
RRID:AB_448163, Cambridge, UK) diluted to 1/5000 for
immunocytochemistry; the monoclonal anti-APP-Nter
anti-Alzheimer Precursor Protein A4 (EMD Millipore
Cat# MAB348 RRID:AB_94882, Saint-Quentin en Yvelines,
France) diluted to 1/100 for immunocytochemistry, and to
1/1000 for western blotting; anti-myc tag (EMD Millipore
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200, anti-myc tag rabbit polyclonal (EMD Millipore
Cat#06-549 RRID: AB_310165) diluted to 1/200, anti-
APP-Cter polyclonal antibody generated in rabbit [44]
diluted to 1/500 for immunocytochemistry; anti-Actin
mouse monoclonal antibody (EMD Millipore MAB
1501R Cat# MAB1501 RRID:AB_2223041), diluted to 1/
10000 for western blotting; anti-NCAM (Sigma-Aldrich
Cat# C9672 RRID:AB_1079450, l’Isle d’Abeau Chesnes,
France) diluted to 1/2000 for western blotting.
Secondary antibodies used for immunocytochemistry
were Donkey anti-rabbit cy3 (Cat# 711-166-152, Jackson
Immuno-research, Interchim, Montluçon, France) diluted
to 1/500, Donkey anti-mouse cy3 (Cat# 715-166-151
Jackson Immuno-research, Interchim), diluted to 1/200
and Donkey anti-mouse Alexa 488 (Cat# 715-546-151
Jackson Immuno-research, Interchim) diluted to 1/200.
Cell surface biotinylation and western blotting
Cell surface biotinylation after siRNAs addition were
carried out on 106 primary neurons at 5 days in vitro
(DIV) as previously described [33]. For PAT1-myc over-
expressed cells, cell surface biotinylation experiments
were performed on 10 × 106 cells at 6 DIV, 24 h after
transfection. Briefly, the cells were washed with cold
PBS-glucose and incubated for 30 min on ice with sulfo-
NHS-biotine (Pierce) at 35 μg/ml. Then the cells were
washed, scrapped in PBS sucrose 0.32 M, homogenized
and centrifugated at 16,000 × g for 30 min at 4°C. The
particulate pellet was solubilized and added to streptavi-
din sepharose beads overnight at 4°C. After 4 washings
the beads were eluted in Laemmli buffer.
Western blotting was performed as previously de-
scribed [33]. Briefly SDS-PAGE in 7.5 or 10% acrylamide
precast gels (Invitrogen, Life Technologies) were per-
formed. After electrophoresis, electrotransfer was carried
out onto PVDF membranes. Immunodetection was proc-
essed as previously described. Secondary goat anti-mouse
horseradish peroxidase antibody (Biorad, Cat# 170–6516,
Marnes-la-Coquette, France) were used and proteins were
detected by chemiluminescence. ECL (Fischer Scientific,
Illkirsch, France) films were quantified by densitometry.
Immunoprecipitation
Neurons at 6 DIV were rinsed two times in PBS and har-
vested in IP buffer: Hepes 10 mM, NaCl 150 mM, CaCl2
2 mM, 1% Triton X 100, protease inhibitors (Complete
EDTA free, Roche Diagnostics, Mannheim, Germany).
After 15 min at room temperature under agitation, the
lysate was centrifuged at 16,000 × g for 45 min at 4°C.
The supernatant was kept and pre-cleared with protein
A Sepharose for 1 h at 4°C. After centrifugation at 800 g
for 10 min at 4°C, the anti-APP-Cter antibody was added
to the supernatant and left overnight at 4°C under rotateagitation. Then protein A sepharose was added and left
2 h at 4°C under rotate agitation. The beads were then
washed two times in IP buffer and a third time in IP
buffer without Triton X 100. The beads were then eluted
in Laemmli buffer and the proteins loaded in 7.5% acryl-
amide gels for SDS-PAGE followed by immunoblots for
APP and PAT1. A negative control of the immunopre-
cipitation was performed in parallel in the absence of
primary antibody.Up-regulation of PAT1
PAT1-myc plasmid was transfected into 5 DIV cortical
neurons (3 x 105 cells per coverslip) via Lipofectamine™
2000 Reagent (Life Technologies) following the manufac-
turer’s instructions.Immunocytochemistry
Immunocytochemistry was performed on 4% parafor-
maldehyde (PFA) fixed cells for 30 min at room tem-
perature. After 3 washes in PBS, in about half of the
experiments the cells were permeabilized with 0.2% Triton
X 100 in saturation buffer (10% fetal calf serum in PBS) for
1 h at 37°C. They were then incubated with the primary
antibody for 1 h at 37°C and after 3 rinses in PBS, cells were
incubated with anti-rabbit cy3 or anti-mouse cy3 for 1 h at
37°C. After 3 rinses in PBS the coverslips were mounted in
a medium containing DAPI.
Immunofluorescence was examined with a TCS SP5
confocal imaging system equipped with DPSS 561 nm and
HeNe 633 nm lasers (Leica Microsystems, Mannheim,
Germany). Eight bit digital images were collected in se-
quential mode with a x63 plan Apochromat oil immersion
objective, a numerical aperture of 1.4, a zoom of 3 and the
pinhole size “airy 1”. Laser intensities and imaging settings
were adjusted for each experiment and subsequently kept
constant. Microscopy was performed at the PICPEN
platform (INSERM, UMR 894).
Pearson’s coefficient was evaluated using Volocity soft-
ware on confocal images.
Integrated density measurements were performed by
Image J software.Cell death quantification
Cell death quantification was carried out 66 h after
siRNA addition using the Cell Titer-Glo-Luminescent
Cell Viability kit (Promega, Charbonnières, France) ac-
cording to the manufacturer’s instructions.Statistical analysis
Statistical analyses were performed respectively using
the analysis of variance (ANOVA) and post-hoc Scheffe’s
tests (Statview).
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